Sugi Predict

Sugi Predict / Compounds / SCHEMBL17106818

SCHEMBL17106818

SCHEMBL17106818

Nc1ncnn2c([C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@H]3OCc3ccccc3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 1/20 0.43
▸ PDE2A O00408 1/20 0.43
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ HSPA5 P11021 1/20 0.38
▸ PTPN1 P18031 8/20 0.38
▸ CDC25B P30305 8/20 0.38
▸ PTPN2 P17706 4/20 0.38
▸ PTPN6 P29350 4/20 0.38
▸ PTPN11 Q06124 4/20 0.38
▸ SSTR1 P30872 1/20 0.38
▸ SSTR2 P30874 1/20 0.38
▸ SSTR4 P31391 1/20 0.38
▸ SSTR3 P32745 1/20 0.38
▸ SSTR5 P35346 1/20 0.38
▸ NT5E P21589 1/20 0.37
▸ GJB2 P29033 1/20 0.37
▸ BCHE P06276 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17106820 1.00 HTR1A (0.43) HTR1APDE2ACA1CA2CA9
SCHEMBL25598746 1.00 HTR1A (0.43) HTR1APDE2ACA1CA2CA9
SCHEMBL22434801 0.91 PDE2A (0.39) HTR1APDE2ACA1CA2CA9
SCHEMBL19227796 0.91 PDE2A (0.49) HTR1APDE2ACA1CA2CA9
SCHEMBL18636426 0.91 PDE2A (0.49) HTR1APDE2ACA1CA2CA9
SCHEMBL29937393 0.88 HTR1A (0.43) HTR1APDE2ACA1CA2CA9
SCHEMBL29937871 0.88 HTR1A (0.43) HTR1APDE2ACA1CA2CA9
SCHEMBL19343920 0.85 HTR1A (0.41) HTR1APDE2ACA1CA2CA9
SCHEMBL22002160 0.85 HTR1A (0.41) HTR1APDE2ACA1CA2CA9
SCHEMBL17106778 0.85 HTR1A (0.41) HTR1APDE2ACA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000698-A1 SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS UNIV MINNESOTA (US) 2026-01-01 — — US disclosed
US-20230338409-A1 NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES MIRACURE BIOTECHNOLOGY LTD (CN) 2023-10-26 — — US disclosed
US-11697666-B2 Methods of preparing carbanucleosides using amides GILEAD SCIENCES, INC. (US) 2023-07-11 — — US disclosed
WO-2022127914-A1 NUCLEOSIDE-THIODIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY PYROTECH (BEIJING) BIOTECHNOLOGY CO., LTD. (CN) 2022-06-23 — — WO disclosed
WO-2021213288-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG 中国科学院上海药物研究所 (CN) 2021-10-28 — — WO disclosed
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-09-17 — — US disclosed
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2019-08-13 — — US disclosed
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-02-21 — — US disclosed
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2018-01-18 — — US disclosed
US-20180002366-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-01-04 — — US disclosed
US-9777035-B2 4′-substituted nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-10-03 — — US disclosed
US-9777035-B2 4′-substituted nucleoside reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2017-10-03 — — US disclosed
US-9701682-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2017-07-11 — — US disclosed
EP-3122752-A1 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-02-01 — — EP disclosed
WO-2015148746-A1 4'-SUBSTITUTED NUCLEOSIDE-DERIVATIVES AS HIV REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — WO disclosed
US-20150274767-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — US disclosed
WO-2015143712-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-10-01 — — WO disclosed
US-8987709-B2 Arylene containing polymer and organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2015-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180002366-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS DUT, HPRT1, RNGTT HTR1A 4006/4885PDE2A 1359/4885CA1 4808/4885
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 HTR1A 544/4885PDE2A 3391/4885CA1 4134/4885
US-11697666-B2 Methods of preparing carbanucleosides using amides NCL, DUT, POLN HTR1A 4192/4885PDE2A 3245/4885CA1 1671/4885
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections SYNJ1, SARS1, SYNJ2 HTR1A 544/4885PDE2A 3391/4885CA1 4134/4885
US-20200289539-A1 NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 HTR1A 3761/4885PDE2A 253/4885CA1 4777/4885
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 HTR1A 544/4885PDE2A 3391/4885CA1 4134/4885
US-20230338409-A1 NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES PNP, MTAP, TYMP HTR1A 2571/4885PDE2A 441/4885CA1 3738/4885
US-20260000698-A1 SARS-COV-2 NSP14 METHYLTRANSFERASE INHIBITORS NSUN2, SARS1, RNMT HTR1A 3411/4885PDE2A 3664/4885CA1 4554/4885
US-20150274767-A1 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS DUT, HPRT1, RNGTT HTR1A 4006/4885PDE2A 1359/4885CA1 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback